Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Myles, Block, Geoffrey A, Chertow, Glenn M, Cooper, Kerry, Fouqueray, Bruno, Moe, Sharon M, Sun, Yan, Tomlin, Holly, Vervloet, Marc, Oberbauer, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
CKD-Mdb
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025329/
https://www.ncbi.nlm.nih.gov/pubmed/32082556
http://dx.doi.org/10.1093/ckj/sfz034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025329/
https://www.ncbi.nlm.nih.gov/pubmed/32082556
http://dx.doi.org/10.1093/ckj/sfz034

Ejemplares similares